Collectively, the anti-tumor immunity in NTRK1/2/3 MT NSCLC was enhanced in some aspect compared with their WT counterparts, especially in patients with NTRK3 MT. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.